Amgen revives corporates from slumber, winning over €6bn orders
US biotechnology company Amgen made its dash into primary corporate bond markets on Thursday with a dual tranche deal that took €2bn out of the market.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: